Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹16 Cr
Revenue (TTM)
₹34 Cr
Net Profit (TTM)
₹-3 Cr
ROE
-15.7 %
ROCE
2 %
P/E Ratio
--
P/B Ratio
1.6
Industry P/E
44.74
EV/EBITDA
34
Div. Yield
0 %
Debt to Equity
3
Book Value
₹--
EPS
₹-4.9
Face value
10
Shares outstanding
7,944,200
CFO
₹19.98 Cr
EBITDA
₹36.77 Cr
Net Profit
₹2.74 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tonira Pharma [Merged]
| 26.3 | -0.8 | 9.1 | -10.6 | -1.2 | -1.7 | 22.7 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tonira Pharma [Merged]
|
19.8 | 15.7 | 33.5 | -3.4 | -7.2 | -35.4 | -- | 1.6 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Manufacture of allopathic pharmaceutical preparations
Incorporated
1992
Chairman
Bhailalbhai B Shah
Managing Director
R K P Verma
Headquarters
Nandesari, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Tonira Pharma Ltd [Merged] is ₹19.75 (BSE) as of 29-May-2012 IST. Tonira Pharma Ltd [Merged] has given a return of -1.23% in the last 3 years.
Since, TTM earnings of Tonira Pharma Ltd [Merged] is negative, P/E ratio is not available.
The P/B ratio of Tonira Pharma Ltd [Merged] is 1.58 times as on 29-May-2012, a 49 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2011
|
0.00
|
1.22
|
|
2010
|
25.15
|
1.80
|
|
2009
|
0.00
|
0.86
|
|
2008
|
0.00
|
1.56
|
|
2007
|
8.26
|
0.69
|
The 52-week high and low of Tonira Pharma Ltd [Merged] are Rs -- and Rs -- as of 05-Apr-2026.
Tonira Pharma Ltd [Merged] has a market capitalisation of ₹ 16 Cr as on 29-May-2012. As per SEBI classification, it is a company.
Before investing in Tonira Pharma Ltd [Merged], assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.25
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.